Article

Summary-data-based mendelian randomisation reveals druggable targets for multiple sclerosis

2020-01-25

Abstract excerpt

<h4>Background</h4> Multiple Sclerosis (MS) is a complex autoimmune disease caused by a combination of genetic and environmental factors. Translation of Genome-Wide Association Study (GWAS) findings in MS into therapeutics and effective preventive strategies has been limited to date. <h4>Methods</h4> We used Summary Data-Based Mendelian Randomisation (SMR) to synthesise findings from public expression quantitati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 12e9f6f5-3059-5af2-89a0-4599c4d2648e
DOI: 10.1101/2020.01.20.907451

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Summary-data-based mendelian randomisation reveals druggable targets for multiple sclerosisDOI 10.1101/2020.01.20.907451Read

Summary-data-based Mendelian randomization prioritizes potential druggable targets for multiple sclerosisSemantic proximity Read

Integrating Genomic, eQTL, and Mendelian Randomization Analyses to Identify Microglial Drug Targets in Multiple Sclerosis.Semantic proximity Read

Prioritization of risk genes in multiple sclerosis by a refined Bayesian framework followed by tissue-specificity and cell type feature assessment.Semantic proximity Read

Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis.Semantic proximity Read

Utilising multi-large omics data to elucidate biological mechanisms within multiple sclerosis genetic susceptibility loci.Semantic proximity Read

Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis.Semantic proximity Read

Integrated multi-omics and machine learning prioritize key immune genes for multiple sclerosis risk prediction.Semantic proximity Read

Epigenetic and genetic insights for tailored therapeutic strategies in multiple sclerosis.Semantic proximity Read

A gene regulatory network approach harmonizes genetic and epigenetic signals and reveals repurposable drug candidates for multiple sclerosisSemantic proximity Read

Integration of genomic variants and bioinformatic-based approach to drive drug repurposing for multiple sclerosisSemantic proximity Read

Multi-omics integration prioritizes potential drug targets for multiple sclerosisSemantic proximity Read

Key genetic biomarkers and therapeutic potential in multiple sclerosis: Insights from integrated bioinformatics and mendelian randomizationSemantic proximity Read